ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib Meeting Abstract
| Authors: | De Langen, J.; Cho, B. C.; Piotrowska, Z.; Le, X.; Goldberg, S. B.; Goldman, J. W.; Okamoto, I.; Hewson, N.; Maidment, J.; Tang, K. H.; Veney, N.; Cosaert, J.; Lau, J.; Dressman, M.; Ambrose, H.; Riess, J. W.; Yu, H. A. |
| Abstract Title: | ORCHARD platform study: Osimertinib plus datopotamab deruxtecan (Dato-DXd) cohort in patients (pts) with advanced NSCLC (aNSCLC) who have progressed on first-line (1L) osimertinib |
| Meeting Title: | ESMO Congress 2022 |
| Journal Title: | Annals of Oncology |
| Volume: | 33 |
| Issue: | Suppl. 7 |
| Meeting Dates: | 2022 Sep 9-13 |
| Meeting Location: | Paris, France |
| ISSN: | 0923-7534 |
| Publisher: | Oxford University Press |
| Date Published: | 2022-09-01 |
| Start Page: | S1091 |
| End Page: | S1092 |
| Language: | English |
| ACCESSION: | WOS:000866211601450 |
| DOI: | 10.1016/j.annonc.2022.07.1311 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 1188TiP -- Source: Wos |
